Menter D, Afshar-Kharghan V, Shen J, Martch S, Maitra A, Kopetz S
Cancer Metastasis Rev. 2022; 41(1):147-172.
PMID: 35022962
PMC: 8754476.
DOI: 10.1007/s10555-022-10019-5.
Williams P, Wernke K, Tirla A, Herzon S
Nat Prod Rep. 2020; 37(11):1532-1548.
PMID: 33174565
PMC: 7700718.
DOI: 10.1039/d0np00072h.
Jing C, Mallah S, Kriemen E, Bennett S, Fasano V, Lennox A
ACS Cent Sci. 2020; 6(6):995-1000.
PMID: 32607446
PMC: 7318075.
DOI: 10.1021/acscentsci.0c00310.
Menter D, Kopetz S, Hawk E, Sood A, Loree J, Gresele P
Cancer Metastasis Rev. 2017; 36(2):199-213.
PMID: 28730545
PMC: 5709140.
DOI: 10.1007/s10555-017-9682-0.
Voon P, Ng T, Lee V, Nesaretnam K
Eur J Clin Nutr. 2015; 69(6):712-6.
PMID: 25804278
DOI: 10.1038/ejcn.2015.26.
Method development and validation for ultra-high pressure liquid chromatography/tandem mass spectrometry determination of multiple prostanoids in biological samples.
Yu R, Zhao G, Christman J, Xiao L, van Breemen R
J AOAC Int. 2013; 96(1):67-76.
PMID: 23513960
PMC: 3723117.
DOI: 10.5740/jaoacint.12-280.
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.
Fitzgerald D, FitzGerald G
Circ Res. 2013; 112(1):174-94.
PMID: 23287454
PMC: 3572712.
DOI: 10.1161/CIRCRESAHA.111.300271.
Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk.
Olson M, Kickler T, Lawson J, McLean R, Jani J, FitzGerald G
J Thromb Haemost. 2012; 10(12):2462-9.
PMID: 23072449
PMC: 3718475.
DOI: 10.1111/jth.12026.
The role of nitric oxide in prostaglandin biology; update.
Kim S
Nitric Oxide. 2011; 25(3):255-64.
PMID: 21820072
PMC: 3190648.
DOI: 10.1016/j.niox.2011.07.002.
Generation and detection of levuglandins and isolevuglandins in vitro and in vivo.
Zhang M, Li W, Li T
Molecules. 2011; 16(7):5333-48.
PMID: 21705973
PMC: 6264246.
DOI: 10.3390/molecules16075333.
Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?.
Ting H, Khasawneh F
J Biomed Sci. 2010; 17(1):24.
PMID: 20370921
PMC: 2854111.
DOI: 10.1186/1423-0127-17-24.
Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.
Charman W, Charman S, Monkhouse D, Frisbee S, LOCKHART E, Weisman S
Br J Clin Pharmacol. 1993; 36(5):470-3.
PMID: 12959298
PMC: 1364623.
DOI: 10.1111/j.1365-2125.1993.tb00399.x.
Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.
Narumiya S, Okuma M, Ushikubi F
Br J Pharmacol. 1986; 88(2):323-31.
PMID: 3730697
PMC: 1916831.
DOI: 10.1111/j.1476-5381.1986.tb10208.x.
Endothelial cell function in diabetic microangiopathy.
Porta M, La Selva M, Molinatti P, MOLINATTI G
Diabetologia. 1987; 30(8):601-9.
PMID: 3308602
DOI: 10.1007/BF00277315.
Isolation and characterization of natural allene oxides: unstable intermediates in the metabolism of lipid hydroperoxides.
Brash A, Baertschi S, Ingram C, Harris T
Proc Natl Acad Sci U S A. 1988; 85(10):3382-6.
PMID: 2835769
PMC: 280213.
DOI: 10.1073/pnas.85.10.3382.
Inhibition of pulmonary thromboxane A2 synthase activity and airway responses by CGS 13080.
McNamara D, Harrington J, Bellan J, Graybar G, Underwood D, Kadowitz P
Mol Cell Biochem. 1989; 85(1):29-41.
PMID: 2725478
DOI: 10.1007/BF00223511.
Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.
Booth R, Honey A, Lad N, Tuffin D, Wade P
Br J Pharmacol. 1989; 96(2):395-405.
PMID: 2522336
PMC: 1854338.
DOI: 10.1111/j.1476-5381.1989.tb11830.x.
Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.
Patscheke H
Blut. 1990; 60(5):261-8.
PMID: 2190651
DOI: 10.1007/BF01736225.